Tocagen Inc (NASDAQ:TOCA) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.

Brokers have set a 12-month consensus price target of $23.67 for the company and are expecting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tocagen an industry rank of 99 out of 265 based on the ratings given to related companies.

Several analysts recently commented on the company. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 price target on shares of Tocagen in a research report on Tuesday, July 25th. Leerink Swann assumed coverage on Tocagen in a research report on Monday, May 15th. They set a “mkt perform” rating and a $19.00 price target for the company. Finally, Evercore ISI reiterated an “outperform” rating and set a $28.00 price target on shares of Tocagen in a research report on Tuesday, May 9th.

Several hedge funds have recently modified their holdings of TOCA. TD Asset Management Inc. purchased a new stake in shares of Tocagen during the second quarter valued at approximately $158,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Tocagen during the second quarter valued at approximately $165,000. Alps Advisors Inc. purchased a new stake in shares of Tocagen during the second quarter valued at approximately $215,000. Bank of New York Mellon Corp purchased a new stake in shares of Tocagen during the second quarter valued at approximately $281,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Tocagen during the second quarter valued at approximately $837,000. Hedge funds and other institutional investors own 0.08% of the company’s stock.

Shares of Tocagen (NASDAQ:TOCA) traded up 0.54% during midday trading on Tuesday, reaching $11.16. 58,059 shares of the company’s stock were exchanged. The stock’s market cap is $221.05 million. Tocagen has a one year low of $9.68 and a one year high of $17.95. The company’s 50-day moving average is $11.64 and its 200-day moving average is $13.70.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings data on Tuesday, May 23rd. The company reported ($4.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.70) by $1.41. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Equities analysts expect that Tocagen will post ($2.79) earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/tocagen-inc-nasdaqtoca-given-23-67-consensus-target-price-by-analysts.html.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.